Details for Patent: 11,559,485

Which drugs does patent 11,559,485 protect, and when does it expire?

Patent 11,559,485 protects CAVHANZA and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 11,559,485

Title:	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
Abstract:	Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In particular, the present disclosure provides a pharmaceutical composition in the form of an orally disintegrating tablet. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.
Inventor(s):	Christian F. Wertz, Tzehaw Chen, Joseph McTarsney, Sarah M. Rieschl, Limin Shi
Assignee:	Flex Pharma LLC
Application Number:	US17/328,548
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 11,559,485

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Flex Pharma	CAVHANZA	nilotinib	TABLET, ORALLY DISINTEGRATING;ORAL	217379-001	May 29, 2026		RX	Yes	No	11,559,485		Y
Flex Pharma	CAVHANZA	nilotinib	TABLET, ORALLY DISINTEGRATING;ORAL	217379-002	May 29, 2026		RX	Yes	Yes	11,559,485		Y

International Family Members for US Patent 11,559,485

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3181361
European Patent Office	4142699
Israel	297776
World Intellectual Property Organization (WIPO)	2021222739